7 Analysts Have This to Say About Maravai LifeSciences
Portfolio Pulse from Benzinga Insights
Analysts have provided various ratings for Maravai LifeSciences (NASDAQ:MRVI) within the last quarter, with 1 bullish, 3 somewhat bullish, and 3 indifferent. The average 12-month price target for the company is $13.0, representing a 31.07% decrease from the previous average price target of $18.86.
August 09, 2023 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Maravai LifeSciences has received mixed ratings from analysts, with an average 12-month price target of $13.0, a significant decrease from the previous target.
The decrease in the average 12-month price target for Maravai LifeSciences indicates a negative sentiment among analysts, which could potentially lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100